NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an in-depth interview with Dr. Christopher Schaber, President and Chief Executive Officer of Soligenix, Inc. (NASDAQ:SNGX). The late-stage biopharmaceutical company is advancing a broad pipeline of therapeutic and vaccine candidates across its two business segments, emphasizing its strategic focus on diversified drug development. Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic hypericin) f ...